Improved preparation of leukocytes for chemiluminescent study of human phagocytic leukocyte-generated reactive oxygen species.
Leukocyte oxidative function was investigated in a more physiological milieu than currently used in the chemiluminescence (CL) technique. Heparinized blood was mixed with 6% dextran-T70 (9:1) and the leukocyte-rich plasma obtained without centrifugation was used for the CL experiments (phagocyte count was adjusted to 0.7 x 10(6)/mL with Hanks' buffer) (method A). In this medium, phagocytes responded to stimulation by opsonized zymosan, producing strong luminescence in the presence of 0.5 mumol/L MCLA. CL was inhibited by superoxide dismutase, suggesting that the luminescence reaction was attributable to O2-. Granulocytes were also prepared by the usual method involving centrifugation and were then suspended in plasma (method B). Oxidative function of phagocytes prepared by the two methods was studied together with whole blood as aliquots diluted with Hanks' buffer up to a factor of 1000. Luminescence reached a peak value at a dilution factor of 16, but at very high dilutions luminescence decreased sharply. Significantly higher luminescence values were obtained with samples from method A. Luminescence of whole blood peaked at a dilution factor of 248 but it was less than the value obtained using samples prepared by method A or B. As samples prepared by method A contain all the leukocyte populations, platelets, residual red cells and plasma proteins, the assay of leukocyte-generated reactive oxygens using CL is attained in more physiological conditions than method B in which leukocytes may be damaged owing to repeated centrifugation and hypotonic shock.
Saniabadi
A R
AR
Institute of Biomedical Science, Terumo Corporation, Kanagawa, Japan.
Nakano
M
M
D001386:Azides / Q000494:pharmacology; D002374:Catalase / Q000494:pharmacology; D002469:Cell Separation / Q000379:methods; D006801:Humans; D007093:Imidazoles; D007202:Indicators and Reagents; D007700:Kinetics; D007962:Leukocytes / Q000166:cytology* / Q000187:drug effects / Q000502:physiology*; D008163:Luminescent Measurements; D010586:Phagocytes / Q000166:cytology* / Q000187:drug effects / Q000502:physiology*; D010587:Phagocytosis; D011719:Pyrazines; D019810:Sodium Azide; D013482:Superoxide Dismutase / Q000494:pharmacology; D013481:Superoxides / Q000097:blood*; D015054:Zymosan / Q000494:pharmacology
D001386:Azides; D007093:Imidazoles; D007202:Indicators and Reagents; D011719:Pyrazines; D013481:Superoxides; C063412:2-methyl-6-(4-methoxyphenyl)-3,7-dihydroimidazo(1,2-alpha)pyrazin-3-one; D015054:Zymosan; D019810:Sodium Azide; D002374:Catalase; D013482:Superoxide Dismutase